Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | ANPEP | P15144 | 2/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067489 | 1.00 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL5281365 | 0.98 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL217031 | 0.98 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL27782840 | 0.90 | SRR (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL20215656 | 0.87 | ALPI (0.44) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL25982857 | 0.86 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL20747605 | 0.86 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21202560 | 0.86 | ALPI (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Leucine SCHEMBL8513294 | 0.85 | SLC7A5 (0.57) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3859116 | 0.85 | SLC7A5 (0.70) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236102-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200325151-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. | 2020-10-15 | — | — | US | disclosed |
| US-10364252-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10035791-B2 | Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2018-07-31 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988394-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170298049-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING STROKE AND USE THEREOF | CHINA MEDICAL UNIVERSITY (TW) | 2017-10-19 | — | — | US | disclosed |
| CN-107208042-A | Fusion proteins, recombinant bacteria and methods of using recombinant bacteria | 斯波根生物技术公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2017007701-A1 | ANTIVIRAL PHOSPHODIAMIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| CN-1950383-A | Phosphonates, monophosphonamides, bisphosphonates for the treatment of viral diseases | GILEAD SCIENCES INC (US) | 2007-04-18 | — | — | CN | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1716162-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060046981-A1 | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2006-03-02 | — | — | US | disclosed |
| US-20060030545-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050222090-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005066189-A1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222090-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | CCNY, CCNO, CCNB3 | ALPI 4137/4885PKM 4553/4885PTGS1 1631/4885 |
| US-20060046981-A1 | Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof | HCCS, RCOR3, MSRB3 | ALPI 4424/4885PKM 4595/4885PTGS1 1908/4885 |
| US-20170298049-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING STROKE AND USE THEREOF | PCSK9, NDUFC2, PCSK7 | ALPI 4609/4885PKM 1411/4885PTGS1 595/4885 |
| US-20200325151-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | ALPI 279/4885PKM 2225/4885PTGS1 1549/4885 |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | ALPI 4221/4885PKM 4594/4885PTGS1 1873/4885 |
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | ALPI 279/4885PKM 2225/4885PTGS1 1549/4885 |
| US-10364252-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | ALPI 279/4885PKM 2225/4885PTGS1 1549/4885 |
| US-11236102-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | ALPI 279/4885PKM 2225/4885PTGS1 1549/4885 |
| US-10035791-B2 | Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof | PCSK9, NDUFC2, PCSK7 | ALPI 4609/4885PKM 1411/4885PTGS1 595/4885 |
| US-20060030545-A1 | Anti-proliferative compounds, compositions, and methods of use thereof | CCNY, CCNO, CCNB3 | ALPI 4076/4885PKM 4469/4885PTGS1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.